IGA Antibody Induced by Immunization With Pneumococcal Polysaccharides Is a Prognostic Tool in Common Variable Immune Deficiencies.

Frontiers in Immunology
Federica PulvirentiI Quinti

Abstract

The evaluation of the response to vaccination in patients with inborn errors of immunity is a tool to evaluate T-dependent and T-independent antibody residual function of B lymphocytes and it is part of the diagnostic definition for Common Variable Immune Deficiencies. Currently used classifications for Common Variable Immune Deficiencies patients are based on the frequency of B cell subsets, and have been proven as a valid instrument for identification of patients at higher risk of infectious and non-infectious complications. This 6-years period observational study delineated the measurement of specific IgA antibodies induced by a 23-valent pneumococcal polysaccharides vaccine by a standardized ELISA for the quantification of IgA antibodies to all 23 pneumococcal serotypes as an additional prognostic marker in 74 CVID patients. The inability to mount an IgA-mediated response against the pneumococcal polysaccharide antigens or the inability to maintain the antibody response over time identified poor IgA CVID responders with severe immunological impairment, great risk of co-morbidities, and poor prognosis. The division of CVID patient into specific IgA-non responders and IgA-responders discriminated better than other CVID classi...Continue Reading

References

Dec 22, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M E ConleyA Etzioni
Feb 8, 2005·The Journal of Allergy and Clinical Immunology·Rita CarsettiIsabella Quinti
Jan 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Federica CapolunghiRita Carsetti
Jun 19, 2008·Cytometry. Part B, Clinical Cytometry·Klaus Warnatz, Michael Schlesier
Oct 28, 2008·The Journal of Allergy and Clinical Immunology·Nathaniel D HareZuhair K Ballas
Nov 17, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Heleen BorgersXavier Bossuyt
Nov 6, 2010·The Journal of Allergy and Clinical Immunology·Irene PugaAndrea Cerutti
Sep 26, 2012·Journal of Clinical Immunology·Katharina SchützUlrich Baumann
Dec 19, 2014·Clinical and Vaccine Immunology : CVI·Thomas M Daly, Harry R Hill
Aug 4, 2015·The Journal of Allergy and Clinical Immunology·Viviana MoscheseIsabella Quinti
Sep 16, 2015·The Journal of Allergy and Clinical Immunology·Francisco A BonillaJames W Verbsky
Nov 14, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Francisco A BonillaKlaus Warnatz
Sep 1, 2018·The Journal of Allergy and Clinical Immunology·Federica PulvirentiIsabella Quinti
Feb 19, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Markus G SeidelUNKNOWN ESID Registry Working Party and collaborators
Mar 27, 2019·The Journal of Allergy and Clinical Immunology·Cinzia MilitoIsabella Quinti
Jul 16, 2019·Gut Microbes·Rebecca L FineMartin A Kriegel
Nov 25, 2019·Clinical Immunology : the Official Journal of the Clinical Immunology Society·J Ochoa-GrullónS Sánchez-Ramón

❮ Previous
Next ❯

Citations

Aug 9, 2020·Scandinavian Journal of Immunology·Filomena Monica CavaliereViviana Moschese
Apr 24, 2021·Frontiers in Cellular and Infection Microbiology·Isabella QuintiRita Carsetti
Jul 3, 2021·Vaccines·Cinzia MilitoFrancesco Cinetto

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

FlowJo ( Tree Star )
CellQuest
EUROCLASS
Stata
GraphPad7

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.